GLP1R and type 2 diabetes mellitus: In pregnant patients with pregestational T2D, periconceptional exposure (from 90 days before the first day of the last menstrual period to the end of the first trimester) to GLP-1 RAs and other second-line antidiabetics was not associated with an increased risk of major congenital malformations compared with insulin.